LRRK2 I2020T mutation is associated with tau pathology

Parkinsonism and Related Disorders

Volumn 18, Issue 7, 2012, Pages 819-823

  Ujiie, Sachiko ^a,b   Hatano, Taku ^a   Kubo, Shin Ichiro ^a   Imai, Satoshi ^a,c   Sato, Shigeto ^a   Uchihara, Toshiki ^d   Yagishita, Saburo ^e   Hasegawa, Kazuko ^f   Kowa, Hisayuki ^b   Sakai, Fumihiko ^g   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e KANAGAWA REHABILITATION CENTER   (Japan)

^f SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^g Saitama Neuropsychiatric Institute   (Japan)

Author keywords

I2020T mutation; LRRK2; PARK8; Pathology; Tau

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN;

ADULT; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUCINE RICH REPEAT KINASE 2 GENE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PARK8 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TAUOPATHY;

BRAIN STEM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS;

EID: 84865341866     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.03.024     Document Type: Article

References (30)

1. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
2. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
3. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006, 29:286-293.
4. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006, 23:329-341.
5. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005, 102:16842-16847.
6. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007, 16:223-232.
7. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006, 9:1231-1233.
8. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006, 15:223-232.
9. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008, 27:2432-2443.
10. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
11. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
12. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., et al. Lrrk2 and Lewy body disease. Ann Neurol 2006, 59:388-393.
13. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006, 59:315-322.
14. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 2007, 78:626-628.
15. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506-1508.
16. Giordana M.T., D'Agostino C., Albani G., Mauro A., Di Fonzo A., Antonini A., et al. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov Disord 2007, 22:275-278.
17. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12:826-828.
18. Melrose H.L., Dachsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010, 40:503-517.
19. Lin C.H., Tsai P.I., Wu R.M., Chien C.T. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3beta. J Neurosci 2010, 30:13138-13149.
20. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002, 51:296-301.
21. Hatano T., Kubo S.I., Imai S., Maeda M., Ishikawa K., Mizuno Y., et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007, 16:678-690.
22. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005, 57:918-921.
23. Hasegawa K., Stoessl A.J., Yokoyama T., Kowa H., Wszolek Z.K., Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 2009, 15:300-306.
24. de Silva R., Lashley T., Gibb G., Hanger D., Hope A., Reid A., et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003, 29:288-302.
25. Uchihara T., Nakamura A., Shibuya K., Yagishita S. Specific Detection of pathological three-repeat tau after pretreatment with potassium permanganate and oxalic acid in PSP/CBD brains. Brain Pathol 2011, 21:180-188.
26. Gaig C., Ezquerra M., Marti M.J., Valldeoriola F., Munoz E., Llado A., et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 2008, 270:94-98.
27. Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
28. Vitte J., Traver S., Maues De Paula A., Lesage S., Rovelli G., Corti O., et al. Leucine-Rich repeat kinase 2 is associated with the Endoplasmic Reticulum in dopaminergic neurons and Accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010, 69:959-972.
29. Cookson M.R., Hardy J., Lewis P.A. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 2008, 1:217-231.
30. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005, 102:18676-18681.